Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the pharmaceutical ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment ...

Notably, Eli Lilly had been a partner of Verve’s. Strategic Fit for Eli Lilly: Diversification and Innovation. On the wings of its blockbuster GLP-1, Zepbound, Eli Lilly is flowing with cash.

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.. Lilly will acquire Verve for $10.50 per share, a premium of ...

Summary. Eli Lilly is acquiring Verve Therapeutics for $10.5/share plus a potential $3/share CVR, totaling up to $13.5/share. The deal values Verve at up to $1.3 billion, reflecting a 113% premium ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with market analysis describing the deal as a “bargain”.

Eli Lilly LLY 0.62 % increase; green up pointing triangle agreed to acquire Verve Therapeutics VERV-0.27 % decrease; red down pointing triangle for about $1 billion upfront, adding a potential ...

Eli Lilly (NYSE:LLY) has agreed to acquire Boston-based gene editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3B. Pursuant to the agreement, Lilly will commence a tender offer to ...

Lilly may also pay as much as $300 million more if Verve’s top drug hits certain research milestones. That would bring the total deal to $1.3 billion, The WSJ reported.